Hypertension
Conditions
Brief summary
Chronic kidney disease (CKD) and hypertension are two closely related common chronic diseases that have serious implications to human health. Hypertension is a major cause for progression of renal disease and a risk factor for cardiovascular disease (CVD). Control of Blood Pressure (BP) to target is now considered to be the main goal in the treatment of patients with CKD. In clinical practice, it is difficult for CKD patients with hypertension to achieve systolic BP (SBP) or diastolic BP (DBP) goal; oftentimes, calcium channel blocker (CCB) class of drugs, for example, nifedipine gastrointestinal therapeutic system (GITS), is used in such patients. Previous data have demonstrated nifedipine to be having a significant dose-response relationship; that is, nifedipine 60 mg provided better BP reduction than 30 mg. However, there are limited studies that have evaluated the efficacy and tolerability of nifedipine GITS 60 mg in Chinese CKD patients with hypertension. Hereby, the objective of this study was to evaluate the effectiveness and tolerability of nifedipine GITS 60 mg treatment in a large cohort of CKD patients with uncontrolled hypertension.
Interventions
DRUGNifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)
Nifedipine GITS 60 mg (once per day)
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Male and female patients aged 18-70 years * Patients diagnosed with CKD (Estimated Glomerular Filtration Rate (eGFR) \>15 mL/min/1.73 m\*2) and hypertension without dialysis/replacement therapy * Patients with uncontrolled hypertension (office SBP ≥140 mmHg and DBP ≥ 80 mmHg) who have received Renin-Angiotensin System Inhibitors (RASI) treatment or have not received RASI treatment because of any contraindications * Patients who haven't received nifedipine GITS 60 mg (once per day) previously * Patients for whom the decision to initiate treatment with nifedipine GITS 60 mg was made as per the investigator's routine treatment practice * Signed informed consent * No participation in an investigational program with interventions outside of routine clinical practice
Exclusion criteria
* Have a contraindication to nifedipine GITS according to the approved prescribing information * Patients participating in an investigational program with interventions outside of routine clinical practice
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in office systolic blood pressure from baseline to week 12 | At week 12 | Change in office systolic blood pressure from baseline to week 12 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in office diastolic blood pressure from baseline to week 12 | At week 12 | Change in office diastolic blood pressure from baseline to week 12 |
| Change in systolic blood pressure and diastolic blood pressure from baseline to week 12 according to baseline SBP stratification | At week 12 | Change in systolic blood pressure and diastolic blood pressure from baseline to week 12 according to baseline SBP stratification, stratified by two subgroups baseline, SBP 140-160 mmHg and ≥ 160 mmHg |
| Change in systolic blood pressure and diastolic blood pressure from baseline to week 12 at different stages of Chronic Kidney Disease | At week 12 | Change in systolic blood pressure and diastolic blood pressure from baseline to week 12 at different stages of Chronic Kidney Disease, stage 1 to stage 5 |
| Systolic blood pressure and diastolic blood pressure control rate at week 12 | At week 12 | Systolic blood pressure and diastolic blood pressure control rate at week 12 |
| Number of participants with adverse events and serious adverse events | At week 12 | — |
Countries
China
Outcome results
None listed